Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene
Open Access
- 1 July 2001
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 15 (7) , 1046-1053
- https://doi.org/10.1038/sj.leu.2402157
Abstract
The heterogeneity of acute myeloid leukemia is reflected in many clinical, biological and genetic features that are used to predict the response to therapy. On the basis of chromosome aberrations patients can be stratified in groups reflecting either good or poor prognosis. However, the majority of patients fall in an ‘intermediate risk’ group. Internal tandem duplications in the hematopoietic growth factor receptor Flt3 have been shown to separate a subset of high risk patients from intermediate or low risk cases. In an attempt to further characterize the heterogeneity of prognosis among the cytogenetic intermediate risk group of AML, we investigated the overall survival, failure-free survival, initial therapy response and relapse rates of 103 patients with de novoAML in relation to autonomous proliferation and the proliferative response to a panel of 10 cytokines in a short-term thymidine incorporation assay. To exclude perturbation of the responses by other (known) risk factors our final intermediate risk population was comprised of patients with intermediate risk cytogenetics, having an age of 60 years of younger and not showing tandem duplications in the Flt3 gene. Among this intermediate risk group, only the responses to M-CSF and IL-1α were found to be predictive for therapy outcome. Results obtained by a 7-day culture with these cytokines revealed two subpopulations characterized by a good and a poor prognosis, respectively. The complete remission rates in these subpopulations were similar, but the relapse rates, failure-free survival and overall survival differed. If further study extends and supports our data, it should be considered to include these patients in the poor risk arms of treatment protocols and offer them intensified treatment or bone marrow transplantation.Keywords
This publication has 24 references indexed in Scilit:
- Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemiaMedical and Pediatric Oncology, 1999
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- Human acute myeloid leukemia cells with internal tandem duplications in the Flt3 gene show reduced proliferative ability in stroma supported long-term culturesLeukemia, 1999
- Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?Bone Marrow Transplantation, 1999
- Expression of the c-kit (CD117) Molecule in Normal and Malignant HematopoiesisLeukemia & Lymphoma, 1998
- Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass IIIGene, 1994
- Cytokine receptor expression in leukaemic cellsLeukemia Research, 1994
- The Expression of FMS, KIT and FLT3 in Hematopoietic MalignanciesLeukemia & Lymphoma, 1994
- Isolation and chromosomal localization of a novel FMS-like tyrosine kinase geneGenomics, 1991
- Proposed Revised Criteria for the Classification of Acute Myeloid LeukemiaAnnals of Internal Medicine, 1985